We highlight that YAP/TAZ are not essential for AR nuclear translocation and transcriptional activation, however, targeting YAP/TAZ or SRF provides a new promising therapeutic avenue to develop to manage prostate tumorigenesis. This evidence concerns the gene YAP1 and prostatitis.